Correction: MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy

Correction: MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy

Bibliographic Details
Main Authors:	Mehmet Altan, Fangxin Hong, John V Heymach, Elizabeth Jiménez-Aguilar, Zihan Wei, Andrew J Plodkowski, Peter Sawan, Jia Luo, Hira Rizvi, Brett W Carter
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-07-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/8/2/e000328corr1.full

Similar Items

Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status
by: Mehmet Altan, et al.
Published: (2020-07-01)

MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy
by: Stephanie Dudzinski, et al.
Published: (2020-06-01)

Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy
by: Ioana Plesca, et al.
Published: (2020-03-01)

Correction: Chronic immune checkpoint inhibitor pneumonitis
by: Erika J Crosby, et al.
Published: (2020-07-01)

Correction to: Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis
by: Hamzah Abu-Sbeih, et al.
Published: (2019-12-01)

Correction: Immune checkpoint inhibitor-associated celiac disease
by: Kenji Fujiwara, et al.
Published: (2020-07-01)

Correction: Efficacy of immune checkpoint inhibitors for in-transit melanoma
by: Masashi Akiyama, et al.
Published: (2020-07-01)

Bladder Cancer Exhibiting High Immune Infiltration Shows the Lowest Response Rate to Immune Checkpoint Inhibitors
by: Shen Pan, et al.
Published: (2019-10-01)

Tumor-Infiltrating Lymphocytes and Breast Cancer: Are Immune Checkpoint Inhibitors Ready for Prime Time in Breast Cancer?
by: Cvetanović Ana, et al.
Published: (2016-12-01)

Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic Efficacy: A Computational Retrospective Study
by: Rong Liu, et al.
Published: (2021-06-01)

Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
by: Hamzah Abu-Sbeih, et al.
Published: (2019-02-01)

Checkpoint Inhibitors and Hepatotoxicity
by: Stephen D. H. Malnick, et al.
Published: (2021-01-01)

Tumor-Infiltrating PD-1hiCD8+-T-Cell Signature as an Effective Biomarker for Immune Checkpoint Inhibitor Therapy Response Across Multiple Cancers
by: Zhenyu Yang, et al.
Published: (2021-09-01)

Bone remodeling by checkpoint inhibitor
by: Hyeongjong Kim, et al.
Published: (2020-09-01)

Determinants of Resistance to Checkpoint Inhibitors
by: Linda Tran, et al.
Published: (2020-02-01)

Immune Checkpoint Inhibitors and the Heart
by: Diana Larisa Mocan-Hognogi, et al.
Published: (2021-09-01)

Checkpoint inhibitors in hematological malignancies
by: Chi Young Ok, et al.
Published: (2017-05-01)

658 Toxicities of single agent and combination immune checkpoint inhibitors in patients with pre-existing autoimmune diseases
by: Jeffrey Weber, et al.
Published: (2020-11-01)

Pleiotropic Effects of Metformin on the Antitumor Efficiency of Immune Checkpoint Inhibitors
by: Wenhui Liu, et al.
Published: (2021-02-01)

Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis
by: Hamzah Abu-Sbeih, et al.
Published: (2019-09-01)

Correction: Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors
by: Sydney Spadinger, et al.
Published: (2020-06-01)

Correction: On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19
Published: (2021-04-01)

Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma
by: Jeroen F. Vermeulen, et al.
Published: (2018-03-01)

Correction: Publisher Correction: Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma
by: Shawn T. Beug, et al.
Published: (2018-07-01)

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
by: Zhaozhen Wu, et al.
Published: (2021-02-01)

Virtual Evolution of HVEM Segment for Checkpoint Inhibitor Discovery
by: Mingjia Yu, et al.
Published: (2021-06-01)

Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer
by: Ryan J. Slovak, et al.
Published: (2021-03-01)

Correction: Is there a link between very early changes of primary and secondary lymphoid organs in 18F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy?
by: Yuan Chen, et al.
Published: (2020-07-01)

Therapeutic potential of DNA methyltransferase inhibitors with immune checkpoint inhibitor therapy in breast cancer
by: Na Luo, et al.
Published: (2018-03-01)

Chronic immune checkpoint inhibitor pneumonitis
by: Joanne Riemer, et al.
Published: (2020-06-01)

The Abscopal Effect in the Era of Checkpoint Inhibitors
by: Ondřej Kodet, et al.
Published: (2021-07-01)

Immune Checkpoint Inhibitors in Special Populations
by: Qianyun Shan, et al.
Published: (2021-08-01)

Immune Checkpoint Inhibitors in the Treatment of HCC
by: Clelia Donisi, et al.
Published: (2021-01-01)

Management of Immune Checkpoint Inhibitor Toxicities
by: Durrechou Q, et al.
Published: (2020-09-01)

Ipilimumab (Immune Checkpoint Inhibitors) Hypophysitis
by: Margot Stagnetto, et al.
Published: (2020-11-01)

Indicators of responsiveness to immune checkpoint inhibitors
by: Bradley D. Shields, et al.
Published: (2017-04-01)

Cardiovascular complications of immune checkpoint inhibitors
by: A. A. Kulievа, et al.
Published: (2020-04-01)

Cardiotoxicity and Mechanisms of Immune Checkpoint Inhibitors
by: DONG Shuang, et al.
Published: (2018-11-01)

Renal damage secondary to checkpoint inhibitors
by: Candela Moliz, et al.
Published: (2020-03-01)

Cardiotoxicity from immune checkpoint inhibitors
by: Lars Michel, et al.
Published: (2019-12-01)